Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database

Acta Oncol. 2018 Jun;57(6):867-872. doi: 10.1080/0284186X.2017.1415460. Epub 2017 Dec 15.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Biomarkers, Tumor / blood*
  • Carcinoma, Non-Small-Cell Lung / blood
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Chemotherapy, Adjuvant
  • Databases, Factual
  • Disease Progression
  • Female
  • Humans
  • Immunotherapy / methods
  • Inflammation / blood*
  • Lung Neoplasms / blood
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Nivolumab / therapeutic use*
  • Programmed Cell Death 1 Receptor / immunology
  • Retrospective Studies
  • Survival Analysis

Substances

  • Antineoplastic Agents, Immunological
  • Biomarkers, Tumor
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab